Preview

Current Pediatrics

Advanced search

CLINICAL AND ECONOMIC ANALYSIS OF ETANERCEPT EFFICACY IN A PATIENT WITH JUVENILE HEUMATOID ARTHRITIS

https://doi.org/10.15690/vsp.v11i1.153

Abstract

Article contains clinical and economic analysis of treatment efficacy of a patient with a poliarticular form of juvenile rheumatoid arthritis (JRA) with soluble TNF receptors — etanercept. Such methods of analysis as «disease value» and «expense–efficacy» were used. It has been shown that «disease value» increases against the background of etarnecept use. However, further analysis has shown that from the «expense–efficacy» point etarnecept use decreases expenses in 6.3 times (both direct and indirect expenses, in 4.3 times using only direct expenses) in comparison to standard antirheumatic treatment, that lays economic grounds for etarnecept use for patients with refractory JRA.

About the Authors

V. A. Malievskii
Bashkir State Medical University, Ufa
Russian Federation
Viktor Arturovich Malievskii, PhD, professor of the Department of Hospital Pediatrics of Bashkir State Medical University


G. R. Gareeva
Bashkir State Medical University, Ufa
Russian Federation


E. I. Alexeeva
Scientific Centre of Children’s Health RAMS, Moscow; Sechenov First Moscow Medical University
Russian Federation


References

1. Cassidy J. T. et al. Texbook of pediatric rheumatology. 6th ed. — 2010. — 794 p.

2. Насонов Е. Л. Метотрексат: перспективы применения в рев- матологии. — М.: Филоматис, 2005. — 200 с.

3. Алексеева Е. И., Валиева С. И., Бзарова Т. М., Денисова Р. В. Метотрексат — «золотой стандарт» лечения ювенильного ревма- тоидного артрита // Вопросы современной педиатрии. — 2011; 10 (1): 42–49.

4. Родионовская С. Р., Никишина И. П. «Эра метотрексата» в дет- ской ревмтологии // Вопросы современной педиатрии. — 2006; 5 (3): 31–39.

5. Сигидин Я. А., Лукина Г. В. Биологическая терапия в ревмато- логии. — М., 2007. — 179 с.

6. Gianinin E. H., Ilowite N. T., Lovell D. J. et al. Long-term safety and effectiveness of etanercept in children with selected cetagories of juvenile idiopathic arthritis // Arthr. Rheum. — 2009; 60 (9): 2794–2804.

7. Horneff G., De Bock F., Foeldari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from German JIA Registry // Ann. Rheum. Dis. — 2009; 68 (4): 519–524.

8. Dhillon S., Lyseng-Williamson K. A., Scott L. Etanercept: a review of its use in the management of rheumatoid arthritis // Drugs. — 2007; 67 (8): 1211–1241.

9. Brennan A., Bansback N., Reynolds A., Conway P. Modelling the cost-effectiveness of Etanercept in adults with rheumatoid arthritis in UK // Rheumatology. — 2004; 43 (1): 62.

10. Kamal K. M. Assensing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologist in patients with rheumatoid arthritis. — 2005.

11. Bansback N. J., Ara R., Barkham N. Estimating the cost and health status consequsnces of treatment with the antagonists in patients with psoriatic arthritis // Rheumatology. — 2006; 45 (8): 1029.

12. Prince F. H., de Bekker-Grob E. W., Twilt M. et al. An analysis of the costs and benefits of etanercept in juvenile idiopathic arthritis // Ann. Rheum. Dis. — 2010; 69 (Suppl. 3): 637.

13. Ревматология: национальное руководство / под ред. Е. Л. Насонова, В. А. Насоновой. — М.: ГЭОТАР-Медицина, 2008. — 720 с.

14. Воробьев П. А., Авксентьева М. В., Юрьев А. С., Сура М. В. Клинико-экономический анализ (оценка, выбор медицинских технологий и управление качеством медицинской помощи). — М.: Издательство «Ньюдиамед», 2004. — 404 с.


Review

For citations:


Malievskii V.A., Gareeva G.R., Alexeeva E.I. CLINICAL AND ECONOMIC ANALYSIS OF ETANERCEPT EFFICACY IN A PATIENT WITH JUVENILE HEUMATOID ARTHRITIS. Current Pediatrics. 2012;11(1):177-186. (In Russ.) https://doi.org/10.15690/vsp.v11i1.153

Views: 924


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)